Primerica, Inc. — Q1 2024 Form 10-Q
Reporting period: Three months ended March 31, 2024; comparisons are with Q1 2023 unless otherwise stated. Primerica distributes term life insurance and third-party financial products through an independent sales force in the U.S. and Canada. Financial statements are unaudited.
Financial performance and position
| Metric | Q1 2024 | Q1 2023 / comparison |
|---|---|---|
| Total revenue | $742.8 million | $690.0 million; up 8% |
| Income before taxes | $179.2 million | $166.9 million; up 7% |
| Net income | $137.9 million | $128.1 million; up 8% |
| Diluted EPS | $3.93 | $3.46; up 14% |
| Operating cash flow | $210.9 million | $175.9 million |
| Cash and cash equivalents | $593.4 million | $613.1 million at December 31, 2023 |
Net income margin was approximately 18.6%, broadly unchanged from the prior-year quarter. Revenue growth reflected higher net premiums, commissions and fees, and net investment income. Net premiums rose 5%; commissions and fees rose 10%; net investment income rose 22% to $37.8 million. Benefits and expenses increased 8%, including higher sales commissions, DAC amortization and operating expenses.
At March 31, total assets were $14.9 billion and stockholders’ equity was $2.19 billion. Debt included $593.9 million of senior notes on the balance sheet and a $1.38 billion surplus note issued by Vidalia Re. The company had no borrowings under its $200 million revolving facility and reported covenant compliance. Management said operating cash flows should provide sufficient liquidity for the next 12 months; potential additional sources include portfolio sales, reducing repurchases or revolver borrowings.
Material changes and operating trends
- Term Life: Segment revenue rose 5% to $440.4 million and pretax income rose 6% to $138.4 million. Direct premiums increased with growth in the in-force book. New policies issued increased to 86,587 from 84,561; policy terminations remained elevated, with the high cost of living cited as a likely contributor.
- Investment and Savings Products: Revenue rose 16% to $243.7 million and pretax income rose 17% to $65.6 million. Product sales increased 20% to $2.77 billion, while client account values rose to $103.3 billion, supported by market appreciation. Net flows were positive but lower than the year-earlier quarter.
- Senior Health: Revenue fell 63% to $6.9 million and the pretax loss widened to $14.2 million. Submitted policies declined to 16,068 from 19,826; management cited fewer licensed agents and a third-party service disruption affecting agent productivity. A $7.8 million negative tail revenue adjustment reflected lower-than-expected renewals. LTV/CAC per approved policy was 1.03, versus 1.05.
- Capital returns: The company repurchased $109.1 million of shares and paid $26.3 million in dividends. Weighted-average diluted shares fell to 34.9 million from 36.8 million, contributing to EPS growth. The board’s $425 million repurchase authorization had approximately $315.9 million remaining at quarter-end.
Outlook, risks and unusual items
- No formal earnings or revenue guidance is provided. Management expects operating cash flows and available funding sources to support liquidity over the next 12 months.
- Management identifies persistently elevated living costs and above-historical term-life policy lapses as risks to demand and persistency. Results are also sensitive to equity markets, interest rates, credit spreads, mortality, reinsurance counterparties and Canadian-dollar movements.
- The available-for-sale fixed-maturity portfolio had a net unrealized loss of approximately $230.6 million versus amortized cost; the filing attributes substantially all unrealized losses to interest rates rather than credit quality and says the company has no present intention to sell. The held-to-maturity LLC Note had a reported unrealized loss of $77.2 million, with no credit loss recognized.
- In April 2024, the company reached an insurance recovery agreement relating to the e-TeleQuote acquisition. It expects to recognize a $50 million gain in Q2 2024.
- Legal disputes, regulatory inquiries and arbitrations arise in the ordinary course. The company says it cannot estimate a possible loss or range for these matters and did not identify a proceeding requiring disclosure in this filing.
- Regulatory uncertainty includes a new U.S. Department of Labor fiduciary-rule package and possible Canadian changes to the company’s mutual-fund compensation model; the potential financial impact of Canadian changes is not quantifiable at this time.
- The Q1 2023 comparative figures were revised for previously identified immaterial LDTI-related errors: net income and EPS increased by $3.0 million and $0.08, respectively, versus the originally reported figures.
Important facts for investors to verify
- Whether term-life persistency and claims experience stabilize, given elevated lapses and ongoing cost-of-living pressures.
- Whether investment product sales and client asset values persist if market performance or net flows weaken.
- Whether Senior Health policy volume, retention and unit economics improve after the service disruption and negative renewal adjustment.
- How the unrealized investment losses, reinsurance recoverables and $1.38 billion surplus-note financing develop, including counterparty and liquidity exposure.
- Whether the anticipated $50 million Q2 insurance recovery is received and recognized as described, and whether regulatory changes affect distribution or compensation.
- The effects of continued share repurchases and dividends on cash, capital flexibility and per-share results.